Launch of OxpZero

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Launch of OxpZero™

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, is pleased to announce that following the signature of a licensing agreement with the University of Oxford to develop and commercialise a novel drug delivery technology, the Company is launching OxpZero™. This is a technology platform that allows acidic and anionic drugs to be administered orally without bad taste or irritation in non-tablet form and without affecting the release properties of the drug in the body.

The OxpZero™ platform includes intellectual property and know-how on the design and use of novel salts of the specific drug, the low cost manufacture of the novel salts and on the formulation and manufacturing of finished products using these. OxpZero™ is ideally suitable for the development of non tablet forms such as liquids, gels, chewables, ODT's (orally disintegrating tablets) where taste, irritation or stability of the drug active or finished product have previously hindered successful results.

The company has already used OxpZero™ to demonstrate taste masked ibuprofen liquid and chewable products without the typical burning sensation on the throat of this active and with the same release profile of standard products. The burning sensation of ibuprofen has prevented the successful formulation of doses over 100mg per 5ml in suspension suitable for the adult patient. OxpZero™ can deliver the first stable adult suspension (400mg/5ml or higher) with zero burn.

Initially, the company is making available OxpZero™ solutions for a range of NSAIDs (non steroidal anti inflammatory drugs) including ibuprofen, diclofenac, mefenamic acid and naproxen, all of which have taste or burning issues to overcome to enable non-tablet formulations, especially at higher doses.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented,

"We are delighted to be officially launching the name of our taste masking technology OxpZero™ , which is now available to be licenced to pharmaceutical companies to formulate, develop and gain regulatory approval for new novel taste masked products. We are initially focusing our efforts on NSAIDs, but our technology can be applied to a range of products across a broad spectrum of therapeutic areas;including statins, antibiotics, gaba-analogues, ACE inhibitors and many other important acidic drugs."

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Hybridan LLP (Broker)

Claire Noyce +44 20 7947 4350

ZAI Corporate Finance (Nominated Adviser)

John Depasquale/ John Treacy +44 20 7060 2220

About Oxford Pharmascience Group Plc

OXP Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

OXP develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.